SynthesisJournal of global antimicrobial resistance2021
Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials.
Synthesis in Journal of global antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis.Infection · 2022Pooled it
- Health system factors related to COVID-19 mortality in Eastern India: Hospital-based cross-sectional study.Journal of family medicine and primary care · 2023Article
- Remdesivir treatment for patients with moderate to severe COVID-19.Turkish journal of medical sciences · 2022Observational
- CoRe study: COVID-19 and remdesivir: An insight into the current health planning and policy.Journal of family medicine and primary care · 2022Article
- Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.Journal of clinical epidemiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.